Abstract
Background: Bromodomain and Extra Terminal (BET) family of bromodomain proteins (BRDs), comprised of four members in humans (BRD2, BRD3, BRD4, and BRDT), has emerged as a promising new cancer target class for small-molecule drug discovery.
Objective: This review discusses the patent literature of BET inhibitors (2010-2017) for the treatment of cancer and other related diseases.
Method: BET proteins act as ‘epigenetic readers' and bind to acetylated lysine residues on the tails of histones H3 and H4. Inhibition of BET proteins for a wide array of therapeutic applications has led to the discovery and development of various BET inhibitors.
Results: The increasing significance of BET inhibitors as a potential anticancer therapeutic has led to an extensive patent activity both from academia and pharmaceutical industry. Several of the BET inhibitors are under clinical development for the treatment of various kinds of cancers.
Conclusion: The unmet needs and challenges associated with BET inhibition for cancer treatment have been portrayed in this review. An insight into the current developments and future prospects has been described as well.
Keywords: BET, BET inhibitors, BRDs, cancer, epigenetics, patent, therapeutic potential.
Recent Patents on Anti-Cancer Drug Discovery
Title:BET Inhibitors as Anticancer Agents: A Patent Review
Volume: 12 Issue: 4
Author(s): Imran Ali, Gildon Choi*Kwangho Lee*
Affiliation:
- Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114,Korea
- Bio-Organic Science Division, Korea Research Institute of Chemical Technology, Daejeon 34114,Korea
Keywords: BET, BET inhibitors, BRDs, cancer, epigenetics, patent, therapeutic potential.
Abstract: Background: Bromodomain and Extra Terminal (BET) family of bromodomain proteins (BRDs), comprised of four members in humans (BRD2, BRD3, BRD4, and BRDT), has emerged as a promising new cancer target class for small-molecule drug discovery.
Objective: This review discusses the patent literature of BET inhibitors (2010-2017) for the treatment of cancer and other related diseases.
Method: BET proteins act as ‘epigenetic readers' and bind to acetylated lysine residues on the tails of histones H3 and H4. Inhibition of BET proteins for a wide array of therapeutic applications has led to the discovery and development of various BET inhibitors.
Results: The increasing significance of BET inhibitors as a potential anticancer therapeutic has led to an extensive patent activity both from academia and pharmaceutical industry. Several of the BET inhibitors are under clinical development for the treatment of various kinds of cancers.
Conclusion: The unmet needs and challenges associated with BET inhibition for cancer treatment have been portrayed in this review. An insight into the current developments and future prospects has been described as well.
Export Options
About this article
Cite this article as:
Ali Imran , Choi Gildon *, Lee Kwangho*, BET Inhibitors as Anticancer Agents: A Patent Review, Recent Patents on Anti-Cancer Drug Discovery 2017; 12 (4) . https://dx.doi.org/10.2174/1574892812666170808121228
DOI https://dx.doi.org/10.2174/1574892812666170808121228 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Histone Deacetylase Inhibitors: Design, Structure-Activity Relationships and Therapeutic Implications for Cancer
Anti-Cancer Agents in Medicinal Chemistry Bacterial Outer Membrane Vesicles: An Emerging Tool in Vaccine Development, as Adjuvants, and for Therapeutic Delivery
Drug Delivery Letters Retraction Notice: Protein Identification in Sub Proteome Fractions of Breast Cancer Cells by OFFGEL-IEF and iTRAQ Labeling
Current Proteomics Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimers Disease: Cathepsin Inhibitors as Potential Therapeutics
CNS & Neurological Disorders - Drug Targets Sphingolipids in Inflammation: Roles and Implications
Current Molecular Medicine Isolation and Boactivities of Furfuran Type Lignan Compounds from Edible Plants
Recent Patents on Food, Nutrition & Agriculture Liposomal Formulation of Monovalent Cholesteryl Cytofectins with Acyclic Head Groups and Gene Delivery: A Systematic Review
Current Pharmaceutical Biotechnology Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy.
Current Molecular Medicine Novel Nor-Homo- and Spiro-Oxetan- Steroids Target the Human Androgen Receptor and Act as Antiandrogens
Current Medicinal Chemistry microRNA Involvement in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Polycistronic Viral Vectors
Current Gene Therapy IMPMD: An Integrated Method for Predicting Potential Associations Between miRNAs and Diseases
Current Genomics Lymphocyte Homing to the Liver
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Genome-Wide Integrated Analyses of Androgen Receptor Signaling in Prostate Cancer Based on High-Throughput Technology
Current Drug Targets Pyrrolidino Analogues of Gefitinib with Improved EGFR Inhibition, Cancer Cell Cytotoxicity, and Pharmacokinetic Properties
Anti-Cancer Agents in Medicinal Chemistry Nicotine Vaccines
CNS & Neurological Disorders - Drug Targets Riboregulators and Metabolic Disorders: Getting Closer Towards Understanding the Pathogenesis of Diabetes Mellitus?
Current Molecular Medicine Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Precursors of Magnetic Resonance Imaging Contrast Agents Based on Cystine-coated Iron-oxide Nanoparticles
Current Physical Chemistry